<DOC>
	<DOCNO>NCT02730819</DOCNO>
	<brief_summary>The purpose research study gather information effectiveness tolerability novel composition exist U.S. Food Drug Administration ( FDA ) approve topical medication treatment moderate severe melasma .</brief_summary>
	<brief_title>Topical Composition Therapy ( 2013-MCN-333 ) Treatment Melasma</brief_title>
	<detailed_description>Subjects moderate severe melasma apply 0.5 gram ( pea-sized ) amount Illuminate Cream topically affect area 20 week . The change Melasma Area Severity Index ( MASI ) score evaluate baseline Weeks 4 , 12 , 20 . The MASI score validate test , calculate subjective assessment 3 factor : Area ( A ) involvement , Darkness ( D ) , Homogeneity ( H ) , forehead , right malar region , leave malar region , chin , correspond 30 % , 30 % , 30 % 10 % total face , respectively . The area involvement 4 area give numeric value 0 6 ( 0 = involvement ; 1 = &lt; 10 % ; 2 = 10 % -29 % ; 3 = 30-49 % ; 4 = 50-69 % ; 5 = 70-89 % ; 6 = 90-100 % ) . Darkness homogeneity rat scale 0 4 ( 0 = absent ; 1 = slight ; 2 = mild ; 3 = mark ; 4 = maximum ) . The score calculate add sum severity rating darkness homogeneity , multiply value area involvement , 4 facial area .</detailed_description>
	<mesh_term>Melanosis</mesh_term>
	<criteria>Informed subject consent obtain patient meet follow inclusion criterion : Male female patient 18 65 year age Moderate severe melasma , measure Melasma Area Severity Index score great equal 16 No prior use topical skinlightening agent 1 month prior study entry Good general health confirm medical history Female patient childbearing potential negative urine pregnancy test agree use effective method birth control remain abstinent treatment . Participants must use birth control entire study least 1 week last application study formulation . Acceptable method birth control include ongoing hormonal contraception method , ( birth control pill , patch , injection , vaginal ring , implant ) , barrier method ( condom diaphragm use spermicide ) , intrauterine device , tubal ligation , abstinence Patients willing capable cooperate extent degree require protocol ; Patients read sign approve informed consent study Vulnerable study population Exposure topical skinlightening agent within 1 month study entry , include : Topical corticosteroid Topical bleaching product Topical retinoids Use systemic preparation within 1 month study entry , include : Systemic corticosteroid Systemic cyclosporine , interferon Systemic acitretin , etretinate , isotretinoin Systemic methotrexate Systemic photoallergic , phototoxic and/or photosensitize drug UV light therapy sunbathe Inability communicate cooperate Principal Investigator and/or Investigators due language problem , poor mental development impair cerebral function Pregnant nursing woman Women plan pregnancy within study period</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>April 2016</verification_date>
</DOC>